Johnson & Johnson (JNJ) Market Cap (1999 - 2026)
Johnson & Johnson (JNJ) market cap from Nov 1, 1999 to Jul 20, 2026. The current Johnson & Johnson (JNJ) market cap is $600B. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Market Cap
Johnson & Johnson (JNJ) Market Cap CAGR table
| Period | CAGR |
|---|---|
| 1 Year TTM | +37.42% |
| 3 Years TTM | +5.82% |
| 5 Years TTM | +4.39% |
| 10 Years TTM | +5.81% |
| All Time TTM | +6.21% |
Annual Market Cap change of Johnson & Johnson (JNJ)
| Year | Market Cap | Change |
|---|---|---|
| 2026 | $600B | +20.31% |
| 2025 | $498B | +43.16% |
| 2024 | $348B | -11.96% |
| 2023 | $395B | -14.82% |
| 2022 | $464B | +3.08% |
| 2021 | $450B | +8.70% |
| 2020 | $414B | +7.78% |
| 2019 | $384B | +11.01% |
| 2018 | $346B | -7.68% |
| 2017 | $375B | +19.19% |
| 2016 | $315B | +10.67% |
| 2015 | $284B | -3.37% |
| 2014 | $294B | +14.01% |
| 2013 | $258B | +33.55% |
| 2012 | $193B | +7.69% |
| 2011 | $179B | +5.47% |
| 2010 | $170B | -4.14% |
| 2009 | $178B | +23.19% |
| 2008 | $144B | -10.30% |
| 2007 | $161B | +1.03% |
| 2006 | $159B | +9.85% |
| 2005 | $145B | -5.23% |
| 2004 | $153B | +22.76% |
| 2003 | $124B | -3.82% |
| 2002 | $129B | -9.12% |
| 2001 | $142B | +12.46% |
| 2000 | $127B | +12.71% |
| 1999 | $112B | N/A |
Comparison Johnson & Johnson (JNJ) market cap with competitors
Johnson & Johnson (JNJ) market cap is $599.62B.
| Ticker | Name | Market Cap | Upside |
|---|---|---|---|
| LLY | Lilly(Eli) & Company | $1.03T | +72.48% |
| ABBV | Abbvie Inc | $432.22B | -27.92% |
| AZN | Astrazeneca plc | $295.54B | -50.71% |
| MRK | Merck & Co Inc | $291.57B | -51.37% |
| NVS | Novartis AG | $288.93B | -51.81% |
| NVO | Novo Nordisk | $224.93B | -62.49% |
| AMGN | AMGEN Inc | $193.39B | -67.75% |
| GILD | Gilead Sciences Inc | $163.57B | -72.72% |
| PFE | Pfizer Inc | $141.25B | -76.44% |
| BMY | Bristol-Myers Squibb Company | $119.63B | -80.05% |
| SNY | Sanofi | $105.20B | -82.46% |
| GSK | GSK Plc | $104.78B | -82.53% |
| BIIB | Biogen Inc | $29.03B | -95.16% |
| GRFS | Grifols SA | $4.91B | -99.18% |
| OGN | Organon & Company | $3.54B | -99.41% |
| AMRN | Amarin Corp | $303.37M | -99.95% |
| SCLX | Scilex Holding Company | $78.29M | -99.99% |
| MIRA | Mira Pharmaceuticals Inc | $39.50M | -99.99% |
| NSRX | Nasus Pharma Ltd | $28.10M | -100.00% |
| MDCXW | Medicus Pharma Ltd warrant | $19.20M | -100.00% |
| MDCX | MDCorp | $13.93M | -100.00% |